Economic analysis of a randomized clinical trial to compare filgrastim- mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 5-10

  Smith, T J ^a   Hillner, B E ^a   Schmitz, N ^a   Linch, D C ^a   Dreger, P ^a   Goldstone, A H ^a   Boogaerts, M A ^a   Ferrant, A ^a   Link, H ^a   Zander, A ^a   Yanovich, S ^a   Kitchin, R ^a   Erder, M H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYTARABINE; ETOPOSIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; AUTOGRAFT; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG MEGADOSE; ECONOMIC ASPECT; FEMALE; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEM CELL;

EID: 0031023134     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.5     Document Type: Article

References (16)

1. Mills W, Chopra R, McMillan A, et al: BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed refractory non-Hodgkin's lymphoma. J Clin Oncol 13:588-595, 1995
2. Chopra R, McMillan AK, Linch DC, et al: The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 81:1137-1145, 1993
3. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
4. Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 341:1051-1054, 1993
5. Klumpp TR, Mangan KF, Goldberg SL, et al: Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: A prospective, randomized trial. J Clin Oncol 13:1323-1327, 1995
6. Beyer J, Schwella N, Zingsem J, et al: Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison. J Clin Oncol 13:1328-1335, 1995
7. Uyl-de Groot CA, Richel DJ, Rutten FFH: Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); A less costly alternative to autologous bone marrow transplantation. Eur J Cancer 30A:1631-1635, 1994
8. Bennett CL, Armitage JL, Armitage GO, et al: Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: 1987 through 1991. J Clin Oncol 13:969-973, 1995
9. Schmitz N, Linch DC, Dreger P, et al: Filgrastim-mobilised peripheral blood progenitor cell transplantation in comparison with autologous bone marrow transplantation: Results of a randomised phase III trial in lymphoma patients. Lancet 347:353-357, 1996
10. Kukull WA, Koepsell TD, Conrad DA, et al: Rapid estimation of hospitalization charges from a brief medical record review. Med Care 24:961-966, 1986
11. Smith TJ, Desch CE, Hillner BE: Analysis of Economic Issues, in Armitage JO, Antman KH (eds): High Dose Cancer Therapy: Pharmacology, Hemopoietins, and Stem Cells. Baltimore, MD, Williams & Wilkins, 1992, pp 127-142
12. Kassirer JP, Angell M: The journal's policy on cost-effectiveness analyses. N Engl J Med 331:669-670, 1994
13. Smith TJ, Hillner BE, Desch CE: Efficacy and cost-effectiveness in oncology: Rational allocation of cancer care resources. J Natl Cancer Inst 85:1460-1474, 1993
14. Uyl-de Groot CA, Okhuijsen SY, Hagenbeek A, et al: Costs of introducing autologous BMT in the treatment of lymphoma and acute leukemia in the Netherlands. Bone Marrow Transplant 15:605-610, 1995
15. Bennett CL, Armitage JL, Gorin NC, et al: Hematopoietic growth factors have different economic effects in a national health system (NHS) system as in a fee-for-service (FFS) system. Blood 82:146, 1993 (suppl 1, abstr)
16. Desch CE, Lasala MR, Smith TJ, et al: The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients following a chemotherapy relapse. J Clin Oncol 10:200-209, 1992